Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)

Conditions: Hepatocellular Carcinoma Interventions: Radiation: Stereotactic body radiotherapy; Drug: Adebrelimab; Drug: Lenvatinib Sponsors: Mian XI Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials